Delivering
treatments
for TB.
We envision a world where no one dies of tuberculosis. We are
dedicated to the discovery, development, and delivery of better,
faster-acting, and affordable cures to help end the TB pandemic.
With poor outcomes, as the WHO reports only a
59%
success rate for all people with drug-resistant TB
People can take an average of
14,000
pills over the course of treatment
With poor outcomes, as the WHO reports only a
59%
success rate for all people with drug-resistant TB
Now there are new options.
Novel regimens can shorten treatment and help reduce the treatment burden for people with highly drug-resistant forms of TB.
For example, patients can now access a
3-drug, all-oral, six month regimen
Fewer than
750
pills over the course of treatment
Approximately
90%
success rate
The future of TB R&D.
We’re working hard to transform treatment for everyone with TB—to be able to treat all forms of TB faster and more effectively.
In
3 months
or less
We believe the compounds are already in our pipeline to make this happen, if we can marshal funding, investments, and political will.
Looking ahead, we’re exploring the area of immunotherapy, with a goal to make TB treatment as short as 7-10 days. This uses the body’s immune system along with effective regimens to fight off infection.
Together, we can end TB.
With political will and funding, we can change the game.
References
1. The Review on Antimicrobial Resistance. Tackling Drug-Resistant Infections Globally. Available at: www.amr-review.org
2. WHO (2021). Global TB Report 2021. Available at:https://www.who.int/publications/i/item/9789240037021
3. Conradie F, et al. Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis. N Eng J Med 2020;382:893-902.